You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMianserin
Accession NumberDB06148
TypeSmall Molecule
GroupsApproved
DescriptionA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine.
Structure
Thumb
Synonyms
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,F)pyrazino(1,2-a)azepine
Mianserina
Mianserine
Mianserinum
Mianseryna
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BolvidonNot Available
DepnonNot Available
LantanonNot Available
LuminNot Available
NorvalNot Available
TolvonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mianserin hydrochloride
ThumbNot applicableDBSALT000957
Categories
UNII250PJI13LM
CAS number24219-97-4
WeightAverage: 264.3648
Monoisotopic: 264.16264865
Chemical FormulaC18H20N2
InChI KeyInChIKey=UEQUQVLFIPOEMF-UHFFFAOYSA-N
InChI
InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
IUPAC Name
5-methyl-2,5-diazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(19),8,10,12,15,17-hexaene
SMILES
CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Piperazino-azepine
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Azepine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsMianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.
Mechanism of actionMianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
Related Articles
AbsorptionAbsorbed following oral administration.
Volume of distributionNot Available
Protein binding90%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-17 hours
ClearanceNot Available
ToxicityOral rat LD50: 780mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9703
Blood Brain Barrier+0.9926
Caco-2 permeable+0.8098
P-glycoprotein substrateSubstrate0.8676
P-glycoprotein inhibitor IInhibitor0.8198
P-glycoprotein inhibitor IINon-inhibitor0.9067
Renal organic cation transporterInhibitor0.7953
CYP450 2C9 substrateNon-substrate0.8269
CYP450 2D6 substrateSubstrate0.895
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateInhibitor0.8218
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8025
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.641
Ames testNon AMES toxic0.8689
CarcinogenicityNon-carcinogens0.9699
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.4247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7801
hERG inhibition (predictor II)Inhibitor0.7369
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.232 mg/mLALOGPS
logP3.52ALOGPS
logP3.83ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)6.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity84.5 m3·mol-1ChemAxon
Polarizability30.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. [PubMed:8764331 ]
  2. de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. [PubMed:8627567 ]
  3. Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. [PubMed:9232538 ]
External Links
ATC CodesN06AX03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (77.9 KB)
Interactions
Drug Interactions
Drug
2-Aminobenzoic AcidThe therapeutic efficacy of 2-Aminobenzoic Acid can be decreased when used in combination with Mianserin.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mianserin.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Mianserin.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Mianserin.
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Mianserin.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the neurotoxic activities of Mianserin.
AbirateroneThe serum concentration of Mianserin can be increased when it is combined with Abiraterone.
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Mianserin.
AclidiniumMianserin may increase the anticholinergic activities of Aclidinium.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Mianserin.
AmiodaroneThe metabolism of Mianserin can be decreased when combined with Amiodarone.
AmobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmphetamineAmphetamine may decrease the sedative activities of Mianserin.
Anisotropine MethylbromideMianserin may increase the anticholinergic activities of Anisotropine Methylbromide.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Mianserin.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Mianserin.
AprepitantThe serum concentration of Mianserin can be increased when it is combined with Aprepitant.
ArtemetherThe metabolism of Mianserin can be decreased when combined with Artemether.
AtazanavirThe metabolism of Mianserin can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Mianserin can be decreased when combined with Atomoxetine.
Atracurium besylateMianserin may increase the anticholinergic activities of Atracurium besylate.
AtropineMianserin may increase the anticholinergic activities of Atropine.
AzithromycinThe metabolism of Mianserin can be decreased when combined with Azithromycin.
BarbexacloneThe therapeutic efficacy of Barbexaclone can be decreased when used in combination with Mianserin.
BarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital.
BeclamideThe therapeutic efficacy of Beclamide can be decreased when used in combination with Mianserin.
BenactyzineMianserin may increase the anticholinergic activities of Benactyzine.
BenmoxinBenmoxin may increase the neurotoxic activities of Mianserin.
BenzatropineMianserin may increase the anticholinergic activities of Benzatropine.
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Mianserin.
BenzphetamineBenzphetamine may decrease the sedative activities of Mianserin.
Benzylpenicilloyl PolylysineMianserin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Mianserin.
BetaxololThe metabolism of Mianserin can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Mianserin.
BexaroteneThe serum concentration of Mianserin can be decreased when it is combined with Bexarotene.
BiperidenMianserin may increase the anticholinergic activities of Biperiden.
BoceprevirThe metabolism of Mianserin can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Mianserin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mianserin can be decreased when it is combined with Bosentan.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mianserin.
BrivaracetamThe therapeutic efficacy of Brivaracetam can be decreased when used in combination with Mianserin.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.
BupropionThe metabolism of Mianserin can be decreased when combined with Bupropion.
CaffeineThe metabolism of Mianserin can be decreased when combined with Caffeine.
CarbamazepineThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mianserin.
CarbamazepineThe metabolism of Mianserin can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the neurotoxic activities of Mianserin.
CelecoxibThe metabolism of Mianserin can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Mianserin can be increased when it is combined with Ceritinib.
ChloroquineThe metabolism of Mianserin can be decreased when combined with Chloroquine.
ChlorphenoxamineMianserin may increase the anticholinergic activities of Chlorphenoxamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Mianserin.
ChlorpromazineThe metabolism of Mianserin can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Mianserin can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Mianserin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Mianserin can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Mianserin can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Mianserin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Mianserin can be decreased when combined with Clemastine.
ClobazamThe therapeutic efficacy of Clobazam can be decreased when used in combination with Mianserin.
ClobazamThe metabolism of Mianserin can be decreased when combined with Clobazam.
clomethiazoleThe therapeutic efficacy of clomethiazole can be decreased when used in combination with Mianserin.
ClomipramineThe metabolism of Mianserin can be decreased when combined with Clomipramine.
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Mianserin.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mianserin.
ClopidogrelThe metabolism of Mianserin can be decreased when combined with Clopidogrel.
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mianserin.
ClotrimazoleThe metabolism of Mianserin can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Mianserin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Mianserin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Mianserin can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Mianserin can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Mianserin can be decreased when combined with Crizotinib.
CyclopentolateMianserin may increase the anticholinergic activities of Cyclopentolate.
CyclosporineThe metabolism of Mianserin can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Mianserin can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Mianserin can be decreased when it is combined with Dabrafenib.
DarifenacinMianserin may increase the anticholinergic activities of Darifenacin.
DarifenacinThe metabolism of Mianserin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Mianserin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Mianserin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Mianserin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mianserin can be decreased when combined with Delavirdine.
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Mianserin.
deramciclaneThe therapeutic efficacy of deramciclane can be decreased when used in combination with Mianserin.
DesipramineThe metabolism of Mianserin can be decreased when combined with Desipramine.
DesloratadineMianserin may increase the anticholinergic activities of Desloratadine.
DexamethasoneThe serum concentration of Mianserin can be decreased when it is combined with Dexamethasone.
DexetimideMianserin may increase the anticholinergic activities of Dexetimide.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mianserin.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Mianserin.
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Mianserin.
DicyclomineMianserin may increase the anticholinergic activities of Dicyclomine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mianserin.
DihydroergotamineThe metabolism of Mianserin can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Mianserin can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Mianserin can be decreased when combined with Diphenhydramine.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Mianserin.
DoramectinThe therapeutic efficacy of Doramectin can be decreased when used in combination with Mianserin.
DoxorubicinThe metabolism of Mianserin can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Mianserin can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Mianserin can be decreased when combined with Dronedarone.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Mianserin.
DuloxetineThe metabolism of Mianserin can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Mianserin can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Mianserin can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Mianserin can be decreased when it is combined with Enzalutamide.
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Mianserin.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Mianserin.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Mianserin.
ErgotamineThe therapeutic efficacy of Ergotamine can be decreased when used in combination with Mianserin.
ErythromycinThe metabolism of Mianserin can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mianserin.
Eslicarbazepine acetateThe serum concentration of Mianserin can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Mianserin.
EthopropazineMianserin may increase the anticholinergic activities of Ethopropazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.
EthotoinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mianserin.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.
EtravirineThe serum concentration of Mianserin can be decreased when it is combined with Etravirine.
EzogabineThe therapeutic efficacy of Ezogabine can be decreased when used in combination with Mianserin.
FelbamateThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mianserin.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin.
FluconazoleThe metabolism of Mianserin can be decreased when combined with Fluconazole.
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mianserin.
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mianserin.
FluoxetineThe metabolism of Mianserin can be decreased when combined with Fluoxetine.
FluvoxamineThe metabolism of Mianserin can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Mianserin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mianserin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Mianserin.
FosphenytoinThe metabolism of Mianserin can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the neurotoxic activities of Mianserin.
Fusidic AcidThe serum concentration of Mianserin can be increased when it is combined with Fusidic Acid.
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mianserin.
GaboxadolThe therapeutic efficacy of Gaboxadol can be decreased when used in combination with Mianserin.
Gallamine TriethiodideMianserin may increase the anticholinergic activities of Gallamine Triethiodide.
GlycopyrroniumMianserin may increase the anticholinergic activities of Glycopyrronium.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Mianserin.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.
HaloperidolThe metabolism of Mianserin can be decreased when combined with Haloperidol.
HexamethoniumMianserin may increase the anticholinergic activities of Hexamethonium.
HexobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
HomatropineMianserin may increase the anticholinergic activities of Homatropine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mianserin.
HydracarbazineHydracarbazine may increase the neurotoxic activities of Mianserin.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Mianserin.
HyoscyamineMianserin may increase the anticholinergic activities of Hyoscyamine.
IdelalisibThe serum concentration of Mianserin can be increased when it is combined with Idelalisib.
IfenprodilThe therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mianserin.
ImatinibThe metabolism of Mianserin can be decreased when combined with Imatinib.
ImipramineThe metabolism of Mianserin can be decreased when combined with Imipramine.
IndinavirThe metabolism of Mianserin can be decreased when combined with Indinavir.
Ipratropium bromideMianserin may increase the anticholinergic activities of Ipratropium bromide.
IproclozideIproclozide may increase the neurotoxic activities of Mianserin.
IproniazidIproniazid may increase the neurotoxic activities of Mianserin.
IsavuconazoniumThe metabolism of Mianserin can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the neurotoxic activities of Mianserin.
IsoniazidThe metabolism of Mianserin can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Mianserin can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Mianserin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Mianserin can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Mianserin can be decreased when combined with Ketoconazole.
LacosamideThe therapeutic efficacy of Lacosamide can be decreased when used in combination with Mianserin.
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mianserin.
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mianserin.
LidocaineThe metabolism of Mianserin can be decreased when combined with Lidocaine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Mianserin.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Mianserin.
LopinavirThe metabolism of Mianserin can be decreased when combined with Lopinavir.
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Mianserin.
LorcaserinThe metabolism of Mianserin can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Mianserin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Mianserin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Mianserin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Mianserin can be decreased when combined with Lumefantrine.
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mianserin.
MebanazineMebanazine may increase the neurotoxic activities of Mianserin.
MecamylamineMianserin may increase the anticholinergic activities of Mecamylamine.
MephentermineMephentermine may decrease the sedative activities of Mianserin.
MephenytoinThe therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mianserin.
MeprobamateThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin.
MethadoneThe metabolism of Mianserin can be decreased when combined with Methadone.
MethamphetamineThe therapeutic efficacy of Methamphetamine can be decreased when used in combination with Mianserin.
MethamphetamineMethamphetamine may decrease the sedative activities of Mianserin.
MethanthelineMianserin may increase the anticholinergic activities of Methantheline.
MetharbitalThe therapeutic efficacy of Metharbital can be decreased when used in combination with Mianserin.
MethohexitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethotrimeprazineThe metabolism of Mianserin can be decreased when combined with Methotrimeprazine.
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.
Methylene blueMethylene blue may increase the neurotoxic activities of Mianserin.
MethylphenobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
MetixeneMianserin may increase the anticholinergic activities of Metixene.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mianserin.
MetoprololThe metabolism of Mianserin can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Mianserin can be decreased when combined with Mexiletine.
MifepristoneThe metabolism of Mianserin can be decreased when combined with Mifepristone.
MinaprineMinaprine may increase the neurotoxic activities of Mianserin.
MirabegronThe metabolism of Mianserin can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Mianserin can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the neurotoxic activities of Mianserin.
ModafinilThe serum concentration of Mianserin can be decreased when it is combined with Modafinil.
N-butylscopolammonium bromideMianserin may increase the anticholinergic activities of N-butylscopolammonium bromide.
NafcillinThe serum concentration of Mianserin can be decreased when it is combined with Nafcillin.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Mianserin.
NefazodoneThe metabolism of Mianserin can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Mianserin can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Mianserin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mianserin can be decreased when combined with Nevirapine.
NialamideNialamide may increase the neurotoxic activities of Mianserin.
NicardipineThe metabolism of Mianserin can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Mianserin can be decreased when combined with Nilotinib.
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mianserin.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Mianserin.
NVA237Mianserin may increase the anticholinergic activities of NVA237.
OctamoxinOctamoxin may increase the neurotoxic activities of Mianserin.
OlaparibThe metabolism of Mianserin can be decreased when combined with Olaparib.
OrphenadrineMianserin may increase the anticholinergic activities of Orphenadrine.
OsimertinibThe serum concentration of Mianserin can be increased when it is combined with Osimertinib.
OxcarbazepineThe therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Mianserin.
OxybutyninMianserin may increase the anticholinergic activities of Oxybutynin.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mianserin.
OxyphenoniumMianserin may increase the anticholinergic activities of Oxyphenonium.
PalbociclibThe serum concentration of Mianserin can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mianserin.
PancuroniumMianserin may increase the anticholinergic activities of Pancuronium.
PanobinostatThe metabolism of Mianserin can be decreased when combined with Panobinostat.
ParaldehydeThe therapeutic efficacy of Paraldehyde can be decreased when used in combination with Mianserin.
ParamethadioneThe therapeutic efficacy of Paramethadione can be decreased when used in combination with Mianserin.
PargylinePargyline may increase the neurotoxic activities of Mianserin.
ParoxetineThe metabolism of Mianserin can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Mianserin can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PentobarbitalThe metabolism of Mianserin can be increased when combined with Pentobarbital.
PentoliniumMianserin may increase the anticholinergic activities of Pentolinium.
PerampanelThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mianserin.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Mianserin.
PhenacemideThe therapeutic efficacy of Phenacemide can be decreased when used in combination with Mianserin.
PhenelzinePhenelzine may increase the neurotoxic activities of Mianserin.
PheniprazinePheniprazine may increase the neurotoxic activities of Mianserin.
PhenobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenobarbitalThe metabolism of Mianserin can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the neurotoxic activities of Mianserin.
PhensuximideThe therapeutic efficacy of Phensuximide can be decreased when used in combination with Mianserin.
PhenterminePhentermine may decrease the sedative activities of Mianserin.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Mianserin.
PhenytoinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Mianserin.
PhenytoinThe metabolism of Mianserin can be increased when combined with Phenytoin.
PipecuroniumMianserin may increase the anticholinergic activities of Pipecuronium.
PirenzepineMianserin may increase the anticholinergic activities of Pirenzepine.
PirlindolePirlindole may increase the neurotoxic activities of Mianserin.
PivhydrazinePivhydrazine may increase the neurotoxic activities of Mianserin.
PosaconazoleThe metabolism of Mianserin can be decreased when combined with Posaconazole.
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mianserin.
PrimidoneMianserin may increase the central nervous system depressant (CNS depressant) activities of Primidone.
PrimidoneThe metabolism of Mianserin can be increased when combined with Primidone.
ProcyclidineMianserin may increase the anticholinergic activities of Procyclidine.
ProgabideThe therapeutic efficacy of Progabide can be decreased when used in combination with Mianserin.
PromazineThe metabolism of Mianserin can be decreased when combined with Promazine.
PropanthelineMianserin may increase the anticholinergic activities of Propantheline.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mianserin.
QuazepamThe serum concentration of Mianserin can be increased when it is combined with Quazepam.
QuinidineMianserin may increase the anticholinergic activities of Quinidine.
QuinidineThe metabolism of Mianserin can be decreased when combined with Quinidine.
QuinineThe metabolism of Mianserin can be decreased when combined with Quinine.
RanolazineThe metabolism of Mianserin can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the neurotoxic activities of Mianserin.
remacemideThe therapeutic efficacy of remacemide can be decreased when used in combination with Mianserin.
RifabutinThe metabolism of Mianserin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Mianserin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Mianserin can be increased when combined with Rifapentine.
RiluzoleThe therapeutic efficacy of Riluzole can be decreased when used in combination with Mianserin.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mianserin.
RitonavirThe metabolism of Mianserin can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Mianserin can be decreased when combined with Rolapitant.
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Mianserin.
RopiniroleThe metabolism of Mianserin can be decreased when combined with Ropinirole.
RufinamideThe therapeutic efficacy of Rufinamide can be decreased when used in combination with Mianserin.
SafrazineSafrazine may increase the neurotoxic activities of Mianserin.
SaquinavirThe metabolism of Mianserin can be decreased when combined with Saquinavir.
ScopolamineMianserin may increase the anticholinergic activities of Scopolamine.
Scopolamine butylbromideMianserin may increase the anticholinergic activities of Scopolamine butylbromide.
SecobarbitalMianserin may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SelegilineSelegiline may increase the neurotoxic activities of Mianserin.
SertralineThe metabolism of Mianserin can be decreased when combined with Sertraline.
SildenafilThe metabolism of Mianserin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Mianserin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mianserin can be increased when it is combined with Simeprevir.
SolifenacinMianserin may increase the anticholinergic activities of Solifenacin.
SorafenibThe metabolism of Mianserin can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Mianserin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mianserin can be increased when it is combined with Stiripentol.
StiripentolThe therapeutic efficacy of Stiripentol can be decreased when used in combination with Mianserin.
SulfisoxazoleThe metabolism of Mianserin can be decreased when combined with Sulfisoxazole.
SULTHIAMEThe therapeutic efficacy of SULTHIAME can be decreased when used in combination with Mianserin.
TelaprevirThe metabolism of Mianserin can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Mianserin can be decreased when combined with Telithromycin.
TenofovirThe metabolism of Mianserin can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Mianserin can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Mianserin can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Mianserin can be decreased when combined with Theophylline.
ThiamylalMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
ThiopentalMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mianserin.
ThioridazineThe metabolism of Mianserin can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Mianserin can be decreased when combined with Thiotepa.
TiagabineThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mianserin.
TiclopidineThe metabolism of Mianserin can be decreased when combined with Ticlopidine.
TiletamineThe therapeutic efficacy of Tiletamine can be decreased when used in combination with Mianserin.
TiotropiumMianserin may increase the anticholinergic activities of Tiotropium.
TipranavirThe metabolism of Mianserin can be decreased when combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin.
TocilizumabThe serum concentration of Mianserin can be decreased when it is combined with Tocilizumab.
ToloxatoneToloxatone may increase the neurotoxic activities of Mianserin.
TolterodineMianserin may increase the anticholinergic activities of Tolterodine.
TopiramateThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin.
tramiprosateThe therapeutic efficacy of tramiprosate can be decreased when used in combination with Mianserin.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the neurotoxic activities of Mianserin.
TranylcypromineTranylcypromine may increase the neurotoxic activities of Mianserin.
TrihexyphenidylMianserin may increase the anticholinergic activities of Trihexyphenidyl.
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mianserin.
TrimethaphanMianserin may increase the anticholinergic activities of Trimethaphan.
TropicamideMianserin may increase the anticholinergic activities of Tropicamide.
TrospiumMianserin may increase the anticholinergic activities of Trospium.
TubocurarineMianserin may increase the anticholinergic activities of Tubocurarine.
UmeclidiniumMianserin may increase the anticholinergic activities of Umeclidinium.
Valproic AcidThe therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mianserin.
ValpromideThe therapeutic efficacy of Valpromide can be decreased when used in combination with Mianserin.
VecuroniumMianserin may increase the anticholinergic activities of Vecuronium.
VemurafenibThe serum concentration of Mianserin can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Mianserin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Mianserin can be decreased when combined with Verapamil.
VigabatrinThe therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mianserin.
VoriconazoleThe metabolism of Mianserin can be decreased when combined with Voriconazole.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mianserin.
ZaleplonThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mianserin.
ZiprasidoneThe metabolism of Mianserin can be decreased when combined with Ziprasidone.
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mianserin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Dekeyne A, Millan MJ: Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin. Neuropharmacology. 2006 Sep;51(4):718-26. Epub 2006 Jun 30. [PubMed:16814817 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Grinshpoon A, Valevski A, Moskowitz M, Weizman A: Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 2000 Sep;15(6):388-90. [PubMed:11004734 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Grinshpoon A, Valevski A, Moskowitz M, Weizman A: Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 2000 Sep;15(6):388-90. [PubMed:11004734 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Csaba G, Kovacs P, Pallinger E: Prolonged effect of the tricyclic antidepressant, mianserin on the serotonin and histamine content of young rats' white blood cells and mast cells. A case of late-imprinting. Pharmacol Res. 2003 Nov;48(5):457-60. [PubMed:12967590 ]
  2. Grinshpoon A, Valevski A, Moskowitz M, Weizman A: Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 2000 Sep;15(6):388-90. [PubMed:11004734 ]
  3. Nowak JZ, Arrang JM, Schwartz JC, Garbarg M: Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: in vitro and in vivo studies and radioreceptor assay. Neuropharmacology. 1983 Mar;22(3):259-66. [PubMed:6302549 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1F
Uniprot ID:
P30939
Molecular Weight:
41708.505 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Olianas MC, Dedoni S, Onali P: The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors. Br J Pharmacol. 2012 Nov;167(6):1329-41. doi: 10.1111/j.1476-5381.2012.02078.x. [PubMed:22708686 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Terai M, Hidaka K, Nakamura Y: Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum. Eur J Pharmacol. 1989 Dec 7;173(2-3):177-82. [PubMed:2576228 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on November 25, 2007 11:28 / Updated on August 17, 2016 12:24